The Kyiv branch of the Ukrainian Institute of Experimental Endocrinology is established. In 1932, the branch releases its first drugs —Hematogen liquid and in tablets.
New production facilities of the Kyiv branch are built. In 1940, the branch produced over 4 million units.
Darnitsa Chemical and Pharmaceutical Plant is established. The company increases its production base.
Glass-blowing and ampoule-tablet workshops are commissioned. Production of injectable solutions increases to 100 million ampoules per year.
New buildings are constructed: chemical and tablet workshops, finished goods warehouse.
Kyiv Industrial Chemical and Pharmaceutical Association Darnitsa is established, consisting of Darnitsa and Borshchahivskyi Chemical and Pharmaceutical Plant, the Kyiv Vitamin Plant, and Monastyryshchenskyi Chemical and Pharmaceutical Plant.
Production facilities begin to be overhauled with imported equipment.
Change of ownership to JSC Pharmaceutical firm Darnitsa. Volodymyr Zahorii is elected Director General.
Darnitsa ranks No. 1 by circulation of medicines in kind. As of now, the company is still the undisputed leader.
Start of production of sterile cephalosporin antibiotics in accordance with GMP requirements.
Independent audit by British experts for compliance with GMP requirements. In 2003, the company receives the first national GMP certificate (production of sterile antibiotics for the preparation of injection solutions in vials).
Darnitsa creates specialized production facilities for macrolide antibiotics and medicines in the form of drops.
The new laboratory facility starts its work in accordance with international standards.
The implemented logistics complex project with 100% process automation is the first and so far only warehouse of this level in the pharmaceutical industry in Ukraine and Eastern Europe.
Full-scale technical reequipment of the ampoule shop floor. Annual production increases to 400 million ampoules.
The first production of infusion solutions in Ukraine opens. Production investments amounts to EUR 20 million.
The company has identified a new development vector - the establishment of an international pharmaceutical brand, complex generics field leadership, the development of fully digital company. At this time, Darnitsa has updated its logo - now it's a rethought microscope that is a symbol of continuous development and retrieval.
Drugs release speed-up from 30 to 18 months. Corporate DWH & BI system implementation. Completion of office renovation as a continuation of a large-scale company transformation.
Darnitsa received the Australian GMP Certificate (Good Manufacturing Practice). Obtaining from WHO the mRNA vaccine production technology. Darnitsa entered into a non-exclusive voluntary licensing agreement with Medicines Patent Pool (MPP) for manufacturing and sale of a generic version of Pfizer's oral COVID-19 treatment candidate nirmatrelvir Opening its own hotline for medicines availability.